New Delhi, July 7 -- Acute Myeloid Leukemia (AML), an aggressive form of blood cancer, has long been a significant challenge for patients and doctors in India.
But recent medical breakthroughs-including the recent approval of targeted therapies in India like Ivosidenib for IDH1 mutated AML - may change the narrative.
"Acute Myeloid Leukemia is a disease where intensive treatment with high dose chemotherapy and bone marrow transplantation had been the only treatments available. With the advent of targeted therapies like Ivosidenib, individual mutations in AML can now be targeted leading to minimal collateral damage to normal blood cells. There is a crying need for such treatments which could simplify the management of this complex disease....